Presentation will be held on Monday, September 12, 2022, from 10:30 a.m. to 11:00 a.m. EDT
NEW
HAVEN, Conn., Sept. 7,
2022 /PRNewswire/ -- Trevi Therapeutics, Inc.
(Nasdaq: TRVI), a clinical-stage biopharmaceutical company
developing an investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of prurigo nodularis and chronic
cough in adults with idiopathic pulmonary fibrosis (IPF), today
announced that Jennifer Good,
President and Chief Executive Officer, will present at the H.C.
Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 a.m. ET. Ms. Good, along with Lisa Delfini, Chief Financial Officer, will also
participate in investor meetings with attendees.
H.C. Wainwright 24th Annual Global Investment Conference
(Hybrid)
Date: Monday, September 12,
2022
Company presentation: Jennifer Good, President and
CEO
Time: 10:30 AM ET
The presentation will be available to attending participants.
For more information about the H.C. Wainwright 24th Annual Global
Investment Conference or to register in-person or virtual please
visit: https://hcwevents.com/annualconference/
About Trevi Therapeutics,
Inc.
Trevi Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of the investigational therapy Haduvio for the
treatment of prurigo nodularis and chronic cough in adults with
idiopathic pulmonary fibrosis. These conditions share a common
pathophysiology that is mediated through opioid receptors in the
central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release
(ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe.
The ĸ- and µ-opioid receptors are known to be critical mediators of
itch, cough and certain movement disorders. Nalbuphine's mechanism
of action may also mitigate the risk of abuse associated with
µ-opioid agonists because it antagonizes, or blocks, µ-opioid
receptors. Parenteral nalbuphine is not currently scheduled as a
controlled substance by the DEA in the United States or
by regulatory authorities in most
of Europe. Trevi intends to propose Haduvio as the
trade name for nalbuphine ER. Nalbuphine ER has been granted Fast
Track designation by the FDA for the treatment of itch in patients
with prurigo nodularis. Its safety and efficacy have not been
evaluated by any regulatory authority.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-at-hc-wainwright-24th-annual-global-investment-conference-301618991.html
SOURCE Trevi Therapeutics, Inc.